Frank Deane
Deane’s replacement is Maria Crowe, who was previously Lilly’s senior VP for global drug product manufacturing.
Also leaving the company is Bryce Carmine, who was leader of Lilly Bio-Medicines.
John Lechleiter, the firm’s chairman, president, and CEO, described Carmine and Deane as "pillars of the company who have had a lasting, worldwide impact on our people and our business.”